Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell lung cancer (NSCLC)

Trial Profile

Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell lung cancer (NSCLC)

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2017

At a glance

  • Drugs Cisplatin (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms PemSplitCisp
  • Most Recent Events

    • 05 Aug 2017 Status changed from recruiting to completed.
    • 04 Dec 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01742767)
    • 07 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top